Study Suggests Infant Ingestion of Certolizumab Pegol Via Breast Milk Is Unlikely

VBCR - October 2017, Vol 6, No 4 - Rheumatic Diseases
Sophie Granger


There is limited evidence regarding the safety of treatment with biologics in women with chronic inflammatory diseases (eg, rheumatoid arthritis, psoriatic arthritis, and Crohn’s disease) who are breastfeeding. However, results from a recent prospective, multicenter, pharmacokinetic clinical trial support the use of certolizumab pegol therapy in mothers who are breastfeeding, and demonstrated that absorption of certolizumab pegol by infants via breast milk is not likely (Clowse ME, et al. Ann Rheum Dis. 2017 Aug 16. Epub ahead of print).

In the CRADLE study, Megan E.B. Clowse, MD, Associate Professor of Medicine, Duke University School of Medicine, Durham, NC, and colleagues, evaluated the concentrations of certo­lizumab pegol in mature breast milk of patients receiving this biologic, and calculated the average daily dose of certo­lizumab pegol potentially ingested by infants being breastfed. In addition, they evaluated the concentration of polyethylene glycol levels in the breast milk, and assessed safety events in mothers and infants.

“While prior studies entailed case reports with few milk samples obtained at varying times after dosing, CRADLE was designed to fully characterize the CZP PK [certolizumab pegol pharmacokinetics] profile in mature milk at steady-state,” Dr. Clowse and colleagues stated.

Between September 8, 2014, and October 30, 2015, they evaluated 17 lactating women who were being treated with certolizumab pegol for an approved indication. Eligible participants had to be ≥6 weeks postpartum, and neither pregnant nor planning to become pregnant during the course of the study.

Mothers in the CRADLE study were given certolizumab pegol in doses of 200 mg every 2 weeks (N = 16) or 400 mg every 4 weeks (N = 1). After receiving ≥3 doses of certolizumab pegol, which is when the investigators considered plasma concentrations of the drug to be at steady-state, the participants had mature breast milk samples collected. Samples were collected on days 0, 2, 4, 6, 8, 10, 12, and 14; the mother treated with certolizumab pegol 400 mg every 4 weeks had an additional sample collected on day 28.

Using optimal analytical methods, Dr. Clowse and colleagues determined the levels of certolizumab pegol and polyethylene glycol in the breast milk. In addition, subgroup analyses were performed based on indications that were present in ≥3 patients (ie, rheumatoid arthritis, Crohn’s disease, and psoriatic arthritis) to determine whether indication had any effect on the transfer of certolizumab pegol into breast milk.

Of the 137 breast milk samples collected, 77 (56%) contained no measurable amount of certolizumab pegol. For 4 of the 17 mothers, all samples collected were below the lower limit of quantification. The estimated average infant dose of certolizumab pegol was 0 to 0.0104 mg/kg daily, and polyethylene glycol was undetectable in 134 of 137 samples.

Results from the subgroup analyses suggested that the transfer of certoliz­umab pegol into breast milk is not associated with the mother’s indication. Dr Clowse and colleagues also noted that they did not identify any new safety issues related to the use of certolizu­mab pegol. Adverse events in mothers reflected the current safety profile of the biologic, and adverse events in infants were consistent with those of similarly aged infants not exposed to the drug.

“These findings suggest that the level of CZP [certolizumab pegol] ingested by the suckling infant is minimal and indicate that continuation of CZP treatment is compatible with breast feeding. The robust clinical evidence from the CRADLE study allows breastfeeding women with chronic inflammatory diseases and their treating physicians to make informed decisions regarding their postpartum treatment,” Dr Clowse and colleagues concluded.

“These findings are reassuring and support continuation of CZP [certoliz­umab pegol] treatment during breast feeding,” they said.

Related Items
FDA Commissioner Urges Insurers to Support Biosimilar Competition, Reduce Rising Drug Costs
Sophie Granger
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Biosimilars
Web-Based Smartphone Application Useful for Monitoring Changes in RA Disease Activity
Sophie Granger
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Rheumatoid Arthritis
Increased Risk for Bone Fracture Is Similar Among Men and Women with Rheumatoid Arthritis
Leslie Wyatt
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Rheumatic Diseases
Certain Occupations Linked to Increased Risk for Rheumatoid Arthritis
Rebecca Bailey
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Rheumatic Diseases
Increased Risk for Erectile Dysfunction Among Men with Gout
Sophie Granger
VBCR - August 2017, Vol 6, No 3 published on August 23, 2017 in Gout
Patients with Autoimmune Diseases May Be at Greater Risk for Dementia
Anne Rowe
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Rheumatic Diseases
ASAS and EULAR Update Guidelines for the Management of Axial Spondyloarthritis
Sophie Granger
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Axial Spondyloarthritis
Cardiovascular Safety of Moderately Dosed Celecoxib Noninferior to Naproxen or Ibuprofen
Sophie Granger
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Arthritis
Addressing Health Issues in Women with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome
Sophie Granger
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Lupus
Lower Risk for Knee Pain Linked to High Dietary Fiber Intake in Patients with Osteoarthritis
Sophie Granger
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Osteoarthritis
Last modified: November 30, 2017
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology